A. Kirkin

发表

Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.

P. Guldberg, J. Zeuthen, P. thor Straten, 1997, Cancer research.

P. Guldberg, K. Dzhandzhugazyan, A. Kirkin, 2018, Nature Materials.

The immunogenic properties of human melanomas and melanoma-associated antigens recognized by cytotoxic T lymphocytes.

J. Zeuthen, K. Dzhandzhugazyan, A. Kirkin, 1998, Bratislavske lekarske listy.

A Human Melanoma Cell Line, Recognized by Both HLA Class I and Class II Restricted T Cells, is Capable of Initiating both Primary and Secondary Immune Responses

J. Zeuthen, G. Gaudernack, A. Kirkin, 1995, Scandinavian journal of immunology.

The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines

J. Becker, I. Svane, P. thor Straten, 2009, Cancer Immunology, Immunotherapy.

Recombinant human single‐chain MHC‐peptide complexes made from E. coli by in vitro refolding: functional single‐chain MHC‐peptide complexes and tetramers with tumor associated antigens

Y. Reiter, C. Cohen, D. Segal, 2000, European journal of immunology.

Ecto‐ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas

J. Zeuthen, P. thor Straten, K. Dzhandzhugazyan, 1998, FEBS letters.

In vivo and in vitro generation of a new altered HLA phenotype in melanoma‐tumour‐cell variants expressing a single HLA‐class‐I allele

J. Zeuthen, F. Garrido, L. Real, 1998, International journal of cancer.

Detection of circulating tumor lysate–reactive CD4+ T cells in melanoma patients

C. C. Fleischer, J. Zeuthen, M. Petersen, 2004, Cancer Immunology, Immunotherapy.

In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes.

J. Becker, P. Guldberg, J. Zeuthen, 1999, Journal of immunology.

Expanded T Cell Clonotypes Comprise High Numbers of Locally In Situ T Cell Responses Against Melanoma

Hansen, J. Becker, P. Guldberg, 1999 .

Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines

J. Zeuthen, P. thor Straten, T. Seremet, 1997, International journal of cancer.

Aberrant p27Kip1 promoter methylation in malignant melanoma

J. Bartek, J. Bártková, P. Guldberg, 2000, Oncogene.

Amino Acid Substitutions in the Melanoma Antigen Recognized by T Cell 1 Peptide Modulate Cytokine Responses in Melanoma-Specific T Cells

C. Geisler, J. Zeuthen, N. Odum, 2000, Journal of immunotherapy.

Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones

J. Zeuthen, P. thor Straten, K. Dzhandzhugazyan, 1999, Cancer Immunology, Immunotherapy.

Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient

J. Zeuthen, F. Garrido, L. Real, 2001, Cancer Immunology, Immunotherapy.

Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study.

J. Rosenberg, M. Claesson, K. Dzhandzhugazyan, 2006, Journal of experimental & clinical cancer research : CR.

Differential modulation by interferon γ of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens

J. Zeuthen, P. thor Straten, A. Kirkin, 1996, Cancer Immunology, Immunotherapy.

Synthetic peptide with antiproliferative activity: a short C-terminal fragment of the human interferon alpha-2 molecule.

A. Danilkovich, A. Kirkin, K. Freze, 1992, Immunology letters.

Interaction of a synthetic peptide of the interferon alpha-2 C-terminal part with human blood leukocytes. Binding to peripheral blood mononuclear cells.

A. Danilkovitch, O. Kolosova, A. Kharitonenkov, 1991, FEBS letters.

In vivo eradication of an established human melanoma by an in vitro generated autologous cytotoxic T cell clone: A SCID use model

J. Zeuthen, A. Kirkin, A. Stenholm, 1998, International journal of cancer.

The p 16-cyclin D / Cdk 4-pRb Pathway as a Functional Unit Frequently Altered in Melanoma Pathogenesis 1

Jesper, Zeuthen, J. Bartek, 2006 .

Cancer Immunology

R. Rees, K. Whaley, A. Robins, 2001, Immunology and Medicine Series.

The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.

J. Bartek, J. Lukas, J. Bártková, 1996, Cancer research.

Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3.

G. Pawelec, J. Zeuthen, H. Kalbacher, 1997, Cancer research.

Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma

P. Guldberg, J. Zeuthen, P. Straten, 1999, Oncogene.

Cancer/Testis Antigens: Structural and Immunobiological Properties

J. Zeuthen, K. Dzhandzhugazyan, A. Kirkin, 2002, Cancer investigation.

Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture.

J. Becker, P. Guldberg, J. Zeuthen, 2000, Clinical immunology.

Methylation-dependent Silencing of the Reduced Folate Carrier Gene in Inherently Methotrexate-resistant Human Breast Cancer Cells*

P. Guldberg, K. Dzhandzhugazyan, J. Worm, 2001, The Journal of Biological Chemistry.

Selective adsorption of immune DNA-synthesizing lymphocytes on corresponding target cells

A. Kirkin, B. D. Brondz, S. Y. Epikhina, 1975, Bulletin of Experimental Biology and Medicine.

Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: A novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma

P. Guldberg, K. Grønbæk, J. Zeuthen, 1997, International journal of cancer.

Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells

H. Ditzel, P. Guldberg, J. Mortensen, 2018, Nature Communications.

Syddansk Universitet Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells

H. Ditzel, P. Guldberg, J. Mortensen, 2018 .

A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma

G. Stragliotto, A. Jakola, H. Carén, 2021, Neuro-oncology advances.

Melanoma‐associated antigens recognized by cytotoxic T lymphocytes

J. Zeuthen, K. Dzhandzhugazyan, A. Kirkin, 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

The Immunogenic Properties of Melanoma-Associated Antigens Recognized by Cytotoxic T Lymphocytes

J. Zeuthen, K. Dzhandzhugazyan, A. Kirkin, 1998, Experimental and Clinical Immunogenetics.

Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients.

J. Zeuthen, K. Hou‐Jensen, A. Birck, 1999, Melanoma research.

Recognition of human tumours: cancer/testis antigens

J. Zeuthen, K. Dzhandzhugazyan, A. Kirkin, 2001 .

Recognition of human tumours: melanoma differentiation antigens

J. Zeuthen, A. Kirkin, 2001 .

Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines

J. Zeuthen, P. Straten, Li Li, 1995, Cancer Immunology, Immunotherapy.

Generation and characterization of GP‐100 peptide‐specific NK‐T cell clones

J. Myklebust, I. Saeterdal, G. Gaudernack, 1998, International journal of cancer.